Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study
- PMID: 18840010
- DOI: 10.2165/00044011-200828110-00001
Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study
Abstract
Background and objectives: Hypertension, one of the major treatable cardiovascular (CV) risk factors, usually occurs in association with other major risk factors. As well as providing rapid blood pressure (BP) goal attainment, antihypertensive therapy should also provide reductions in CV events and mortality in a wide range of patients. For this, higher dosages and combinations of antihypertensive agents are often required. ACE inhibitors are recommended as first-line agents for control of hypertension in patients with additional CV risk factors. The PEACH (Perindopril's Effect At Controlling Hypertension) study was a community-based study performed to evaluate the effectiveness and safety of high-dose perindopril in patients with mild-to-moderate hypertension and additional risk factors for CV disease.
Methods: This was an open-label, multicentre observational study conducted in Canadian general practice clinics. The study assessed the efficacy and tolerability of perindopril given once daily for 10 weeks uptitrated to the maximal recommended dose of perindopril as required for BP control in newly diagnosed or previously treated patients with uncontrolled mild to moderate hypertension and >or=1 additional risk factor. Patients not achieving target BP after 2 weeks of therapy were uptitrated from perindopril 4 mg to perindopril 8 mg once daily. Efficacy endpoints included reduction in systolic (SBP) and diastolic (DBP) BP and BP control. Tolerability assessments included adverse effects and physicians' assessment of tolerability. The number of missed doses was also recorded.
Results: Overall, 2220 patients with hypertension and >or=1 other risk factor were prescribed perindopril at 291 centres; 51.9% were male, 78.3% Caucasian, 12.8% Asian, 36.2%>or=65 years of age and 34.5% had uncontrolled BP despite previous antihypertensive treatment. Compared with previously treated patients, treatment-naive patients had fewer risk factors, and a higher proportion were Asian (p<0.05 for all comparisons). Most patients (76%) had 1-2 risk factors. Perindopril produced significant SBP/DBP reductions at 2 and 10 weeks (-15.8/-8.0 and -21.1/-11.0 mmHg, respectively). Overall, at week 10, BP control rate was 53.6%, better than at week 2 in the overall cohort and in all subgroups. Uptitration to high-dose perindopril to achieve BP control was required in 46% of patients with one additional risk factor compared with 64% of patients with >or=4 additional risk factors. These results demonstrate that the more risk factors the patient has, the greater the need for high-dose perindopril to achieve BP control. Perindopril was well tolerated as indicated by the high proportion of physicians (95.9%) reporting 'good' to 'excellent' tolerability at week 10.
Conclusion: In this community-based clinical practice trial, up to 10 weeks' perindopril therapy, uptitrated to the maximal recommended dose as required for BP control, significantly reduced SBP/DBP in patients with mild-to-moderate hypertension and additional CV risk factors. Patients with more risk factors were more likely to require high-dose perindopril.
Similar articles
-
Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: an open-label, prospective, observational study.Clin Drug Investig. 2009;29(12):767-76. doi: 10.2165/11319700-000000000-00000. Clin Drug Investig. 2009. PMID: 19888783 Clinical Trial.
-
Simplified Approach to Managing Newly Diagnosed Patients with Mild-to-Moderate Hypertension in Routine Clinical Practice.Adv Ther. 2025 Feb;42(2):1108-1130. doi: 10.1007/s12325-024-03091-6. Epub 2024 Dec 28. Adv Ther. 2025. PMID: 39731708 Free PMC article.
-
Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study.Curr Vasc Pharmacol. 2016;14(6):570-575. doi: 10.2174/1570161114666160722112110. Curr Vasc Pharmacol. 2016. PMID: 27456109
-
Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.Vasc Health Risk Manag. 2014 Apr 5;10:189-200. doi: 10.2147/VHRM.S59429. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 24741317 Free PMC article. Review.
-
Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.Expert Rev Cardiovasc Ther. 2009 Apr;7(4):345-60. doi: 10.1586/erc.09.2. Expert Rev Cardiovasc Ther. 2009. PMID: 19379059 Review.
Cited by
-
Optimization of blood pressure treatment with fixed-combination perindopril/amlodipine in patients with arterial hypertension.Clin Drug Investig. 2012 Sep 1;32(9):603-12. doi: 10.1007/BF03261915. Clin Drug Investig. 2012. PMID: 22877321 Clinical Trial.
-
Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational Studies.Adv Ther. 2022 Jan;39(1):391-404. doi: 10.1007/s12325-021-01958-6. Epub 2021 Nov 10. Adv Ther. 2022. PMID: 34755324 Free PMC article.
-
Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomized controlled trial.J Clin Hypertens (Greenwich). 2019 Jul;21(7):1002-1008. doi: 10.1111/jch.13557. Epub 2019 Jun 8. J Clin Hypertens (Greenwich). 2019. PMID: 31175711 Free PMC article. Clinical Trial.
-
Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.Ther Clin Risk Manag. 2015 May 18;11:807-19. doi: 10.2147/TCRM.S82049. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 26056460 Free PMC article. Review.
-
Switching from a Free Association of Perindopril/Amlodipine to a Fixed-Dose Combination: Increased Antihypertensive Efficacy and Tolerability.Clin Drug Investig. 2016 Jul;36(7):591-8. doi: 10.1007/s40261-016-0404-0. Clin Drug Investig. 2016. PMID: 27113228
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous